Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorWake Forest University Health Sciences
About this trial
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Eligibility criteria
Qualifiers
Age > 18 years or older
Able to provide informed consent
Primary diagnosis AFF RVR greater than or equal to 120 bpm
Diltiazem as rate control agent
Disqualifiers
Hemodynamically unstable patients (SBP <90, MAP <65)
Impaired consciousness
End stage renal disease on hemodialysis or peritoneal dialysis
Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
Trial design
Treatments tested in this trial
- Magnesium Sulfate 2 G
- Magnesium Sulfate 4 G
- Saline
Treatment groups
153 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov